Abstract
Development of pancreatic cancers is clinically so silent in general that at the time of diagnosis, the vast majority of cases are incurable with a very poor prognosis. Therefore, effective preventive approaches against this aggressive disease are urgently required. Experimentally, carcinogenesis process is assumed to consist of at least two stages named initiation and promotion. Using a two-stage model of hamster pancreatic carcinogenesis, we have reported stage-specific inhibitory effects by a number of potent cancer chemopreventive agents. Among them, phenethyl isothiocyanate (PEITC), a constituent of cruciferous vegetables, remarkably blocked the initiation phase of pancreatic as well as lung carcinogenesis in hamsters initiated with N-nitrosobis(2-oxopropyl)amine (BOP). However, PEITC failed to affect both pancreatic and lung carcinogenesis when given during the post-initiation (promotion) phase of carcinogenesis. In contrast, our recent study clearly demonstrated that a cyclooxygenase (COX)-2 inhibitor substantially protects against BOP-induced pancreatic tumors in hamsters in line with decrease in cell proliferative activity of pancreatic ducts when given in the post-initiation phase. Interestingly, trypsin inhibitors inhibited both initiation and post-initiation phases of BOP-induced pancreatic carcinogenesis although they are known to induce hyperplastic acinar lesions in the rat pancreas. Taken together with these data, our review is aimed at looking over mechanistic insights into potent chemopreventive agents against pancreatic cancer.
Keywords: chemopreventiveagents, pancreatic cancer, n-nitrosobis(2-oxopropyl)amine, phenethyl isothiocyanate
Current Cancer Drug Targets
Title: Potent Chemopreventive Agents Against Pancreatic Cancer
Volume: 4 Issue: 4
Author(s): Akiyoshi Nishikawa, Fumio Furukawa, In-Seon Lee, Takuji Tanaka and Masao Hirose
Affiliation:
Keywords: chemopreventiveagents, pancreatic cancer, n-nitrosobis(2-oxopropyl)amine, phenethyl isothiocyanate
Abstract: Development of pancreatic cancers is clinically so silent in general that at the time of diagnosis, the vast majority of cases are incurable with a very poor prognosis. Therefore, effective preventive approaches against this aggressive disease are urgently required. Experimentally, carcinogenesis process is assumed to consist of at least two stages named initiation and promotion. Using a two-stage model of hamster pancreatic carcinogenesis, we have reported stage-specific inhibitory effects by a number of potent cancer chemopreventive agents. Among them, phenethyl isothiocyanate (PEITC), a constituent of cruciferous vegetables, remarkably blocked the initiation phase of pancreatic as well as lung carcinogenesis in hamsters initiated with N-nitrosobis(2-oxopropyl)amine (BOP). However, PEITC failed to affect both pancreatic and lung carcinogenesis when given during the post-initiation (promotion) phase of carcinogenesis. In contrast, our recent study clearly demonstrated that a cyclooxygenase (COX)-2 inhibitor substantially protects against BOP-induced pancreatic tumors in hamsters in line with decrease in cell proliferative activity of pancreatic ducts when given in the post-initiation phase. Interestingly, trypsin inhibitors inhibited both initiation and post-initiation phases of BOP-induced pancreatic carcinogenesis although they are known to induce hyperplastic acinar lesions in the rat pancreas. Taken together with these data, our review is aimed at looking over mechanistic insights into potent chemopreventive agents against pancreatic cancer.
Export Options
About this article
Cite this article as:
Nishikawa Akiyoshi, Furukawa Fumio, Lee In-Seon, Tanaka Takuji and Hirose Masao, Potent Chemopreventive Agents Against Pancreatic Cancer, Current Cancer Drug Targets 2004; 4 (4) . https://dx.doi.org/10.2174/1568009043332970
DOI https://dx.doi.org/10.2174/1568009043332970 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Latest Insights into the Anticancer Activity of Gold(III)-Dithiocarbamato Complexes
Anti-Cancer Agents in Medicinal Chemistry Monoclonal Antibodies in the Management of Solid Tumors
Current Topics in Medicinal Chemistry Lung Cancer Epidemiology - A Global View
Current Respiratory Medicine Reviews Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry Management of Locally Advanced Cancer Cervix an Indian Perspective
Reviews on Recent Clinical Trials Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Pharmacogenomics in Colorectal Cancer
Current Pharmacogenomics Medicinal Chemistry and Pharmacological Effects of Farnesoid X Receptor (FXR) Antagonists
Current Topics in Medicinal Chemistry Stem Cell Genetic Therapy for Fanconi Anemia – A New Hope
Current Gene Therapy TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery CFTR and MDR: ABC Transporters with Homologous Structure but Divergent Function
Current Genomics Therapeutic Potential of Natural Compounds in Lung Cancer
Current Medicinal Chemistry Celastrol Inhibits the Proliferation and Decreases Drug Resistance of Cisplatin- Resistant Gastric Cancer SGC7901/DDP Cells
Anti-Cancer Agents in Medicinal Chemistry Imidazoquinolines: Recent Developments in Anticancer Activity
Mini-Reviews in Medicinal Chemistry Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design The Potential Role of Radiation Therapy in Bowens Disease: A Review of the Current Literature
Reviews on Recent Clinical Trials